Global Longlife Hospital SME
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 21 Apr 2022 – 25 Apr 2022
- Listing date
- 04 May 2022
- Face value
- ₹10 per share
- Issue price
- ₹140 per share
- Lot size
- 1,000 shares
- Total issue size
- ₹49 Cr
- Market cap at offer price
- ₹147 Cr
- Promoter holding
- 81.43% → 54.29% pre-issue → post-issue
- ISIN
- INE0J2K01014
- Registrar
- Bigshare Services Pvt.Ltd.
- Lead managers
- Interactive Financial Services Ltd.
- Registered office
- Global Hospital, Opp.Auda Garden, Nr.Water Tank, Bodakdev, Gujarat
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Market maker | 1,76,000 | — | — |
Application size
Minimum 1,000 shares per lot, in multiples, at ₹140
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 1,000 | ₹1,40,000 |
| S-HNI (min) | 2 | 2,000 | ₹2,80,000 |
| S-HNI (max) | 7 | 7,000 | ₹9,80,000 |
| B-HNI (min) | 8 | 8,000 | ₹11,20,000 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 1.48 | — |
| P/E (×) | 94.59 | — |
| Market cap | — | ₹147 Cr |
Key performance indicators
- Return on net worth
- 11.54%
- Debt / equity
- 1.36
- NAV per share
- ₹12.81
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Global Longlife Hospital SME
Global Longlife Hospital and Research Limited was incorporated on January 20, 2012 as a private limited company and converted to a public limited company on August 31, 2021. The company operates a 110-bed multi-specialty tertiary care hospital in Bodakdev, Ahmedabad, Gujarat. As of December 31, 2021, the hospital had 11 full-time consultants and a team of more than 30 experienced doctors as consultants, supported by 37 nurses and more than 50 paramedical, corporate and support staff members. The company generates revenue by providing a platform to doctors for treating their patients, offering a range of medical and surgical specialties. The hospital is NABH-accredited and has been awarded 'The Best Emerging Hospital' by Times of India.
Company Analysis
from RHPGlobal Longlife Hospital and Research Limited is a multi-specialty tertiary care hospital in Ahmedabad, Gujarat with 110 beds providing medical and surgical services.
Global Longlife Hospital and Research Limited was incorporated on January 20, 2012 as a private limited company and converted to a public limited company on August 31, 2021. The company operates a 110-bed multi-specialty tertiary care hospital in Bodakdev, Ahmedabad, Gujarat. As of December 31, 2021, the hospital had 11 full-time consultants and a team of more than 30 experienced doctors as consultants, supported by 37 nurses and more than 50 paramedical, corporate and support staff members. The company generates revenue by providing a platform to doctors for treating their patients, offering a range of medical and surgical specialties. The hospital is NABH-accredited and has been awarded 'The Best Emerging Hospital' by Times of India.
Objects of the Issue
- Acquire Land on Leasehold Basis ₹2,000.00 Lakhs p.17
- Repayment of Loan ₹1,480.00 Lakhs p.17
- General corporate purposes ₹1,070.00 Lakhs p.17
- Repayment of borrowings
- Funding capex for land acquisition on lease basis for future expansion of the Hospital Rs. 2,000 Lakhs (deposit) + Rs. 1,00,000 monthly token rent p.112
- General corporate purposes
- Not explicitly stated in Part 3 - Objects of the Offer section not provided in this document section
Issue Structure
- Total Issue
- ₹4,900.00 Lakhs
- Fresh Issue
- 35,00,000 Equity Shares of face value of ₹10.00/- each at a price of ₹140.00/- per share
- Price Band
- ₹140.00 per Equity Share (Fixed Price Issue)
- Lot Size
- 1,000 Equity Shares
- Face Value
- ₹10.00 per Equity Share
Business Model
The company operates as a multi-specialty tertiary care hospital providing medical and surgical services. Doctors with more than 3 years of experience can admit their patients to the hospital. The company provides the platform and infrastructure for doctors to treat patients, charging for hospital services including accommodation, diagnostic services, surgical procedures, and other medical treatments.
Business Segments
SWOT Analysis
- • Multi-specialty tertiary care hospital with modern infrastructure and 110 beds(p.18)
- • Platform model with experienced consultant doctors across multiple specialties(p.18)
- • Strong medical and support staff capacity(p.18)
- • NABH accreditation demonstrating quality standards(p.23)
- • Recently improved profitability with PAT of Rs 103.54 lakhs in FY 2020-21(p.23)
- • Improved financial performance in recent period with PAT of Rs 386.31 lakhs for 9-month period ended December 31, 2021(p.32)
- • Multi-specialty tertiary care hospital with NABH accreditation and comprehensive services(p.71)
- • Prime location in developed area of Ahmedabad with good road connectivity(p.75)
- • Advanced medical equipment and technology infrastructure including cardiac lab, CT scan, and dialysis facilities(p.75)
- • Strong team of experienced medical professionals and consultants(p.75)
- • In-house pathology laboratory with ISO 15189:2012 compliance(p.72)
- • Adequate oxygen and power infrastructure with backup systems(p.84)
- • Integrated hospital management system for clinical and administrative functions(p.72)
- • High dependence on consultant doctors who can work for competing hospitals(p.21)
- • History of net losses with net loss of Rs 86.24 lakhs in FY 2019-20(p.23)
- • Non-compliance with Companies Act regarding director loans(p.23)
- • Outstanding litigations against the company(p.24)
- • Unsecured loans from directors repayable on demand(p.24)
- • Contingent liability from corporate guarantee of Rs 1489.33 lakhs(p.28)
- • Single location operations concentrated in Ahmedabad(p.28)
- • High debt burden with total borrowings of Rs 1536.71 lakhs as at December 31, 2021(p.19)
- • Significant loss in FY2019-20 with negative profit after tax(p.71)
- • Heavy dependence on few customers for revenue concentration(p.71)
- • High debt burden with significant long-term and short-term borrowings(p.120)
- • Concentrated geographic presence limited to Ahmedabad(p.75)
- • High trade receivables concentration with 80% outstanding over 6 months(p.138)
- • Significant dependence on director loans for working capital(p.130)
- • High leverage with debt-to-equity ratio of 1.04 pre-IPO(p.156)
- • Contingent liability from personal guarantee to director's lender(p.143)
- • Litigation involving promoter under Negotiable Instrument Act for dishonored cheque(p.161)
- • Hospital expansion on adjacent leasehold land for new healthcare services(p.54)
- • Addition of advanced medical imaging facilities including PET scan, BMD and MRI(p.54)
- • Expansion of oncology services with dedicated post-operative facilities(p.55)
- • Development of in-house IVF center for gynecological services(p.55)
- • Expansion of physiotherapy and pain management OPD services(p.54)
- • Expansion of ophthalmology services with surgical capabilities(p.54)
- • Growth in India's healthcare industry with cost competitive advantage(p.18)
- • Reduction of debt burden to improve financial flexibility for future expansion(p.56)
- • Significant expansion potential in Tier-2 and Tier-3 cities around Ahmedabad(p.75)
- • Large investment opportunities in hospital/medical infrastructure sector(p.69)
- • Rapidly growing Indian healthcare sector with 22% CAGR since 2016(p.65)
- • Emerging telemedicine market projected to grow at 31% CAGR till 2025(p.70)
- • Growing demand for tertiary and specialty hospital services in India(p.68)
- • Government increased healthcare budget allocation signaling policy support(p.68)
- • Expansion of multi-specialty hospital services(p.149)
- • Growth in COVID-related healthcare services demonstrated in financial performance(p.139)
- • Adoption of cashless payment models through government schemes(p.139)
- • Loss of doctor consultants to competing hospitals due to better opportunities(p.21)
- • Need for continuous capital investment in medical equipment upgradation(p.22)
- • Stringent regulatory compliance requirements in healthcare industry(p.22)
- • Risk of medical negligence claims and regulatory actions(p.23)
- • Competition from large corporate hospitals and established healthcare providers(p.28)
- • Vulnerability to changes in regulatory framework and government policies(p.29)
- • Dependence on India's economic growth for revenue generation(p.29)
- • Vulnerability to natural calamities and external disruptions(p.29)
- • Market volatility risk for equity shares after listing(p.28)
- • Risk from COVID-19 pandemic impact on healthcare business(p.14)
- • Intense competition from established hospital chains in metro and Tier-1 cities(p.68)
- • COVID-19 pandemic impact on hospital operations and planned procedures(p.68)
- • Complex regulatory requirements and compliance burden on healthcare providers(p.87)
- • Dependence on skilled medical professionals with shortage and high turnover risk(p.69)
- • Vulnerability to changes in healthcare policies and reimbursement mechanisms(p.68)
- • Exposure to input cost inflation and supply chain disruptions for medical supplies(p.75)
- • Revenue decline of 2.51% year-over-year in FY 2021(p.150)
- • Government compliance requirements and regulatory restrictions on healthcare operations(p.149)
- • Multiple consumer complaints regarding insurance claim disallowances(p.157)
- • Competition from existing and new healthcare providers(p.149)
- • Difficulty in retaining experienced medical professionals(p.149)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Sureshkumar Babulal Jani | Promoter | 21.43% | 14.29% |
| Dhruv Sureshkumar Jani | Promoter | 34.27% | 22.85% |
| Sucheta Jani | Promoter Group | 25.71% | 17.14% |
| Aruna Jani | Promoter Group | 0.01% | 0.01% |
| Sureshkumar Jani | Promoter | 21.43% | — |
| Dhruv Jani | Promoter | 34.27% | — |
| Mr. Dhruv S Jani | Promoter/Director | — | — |
| Mr. Rajesh Kashiram Agrawal | Promoter | — | — |
| Mr. Suresh Jani | Promoter/Director | — | — |
Leadership
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.